CXLO is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/30/22 | $32,000,000 | Series A |
AXA IM Alts | undisclosed |
